Macroaxis considers Blueprint Medicines to be not too volatile. Blueprint Medicines
secures Sharpe Ratio (or Efficiency) of -0.004 which signifies that Blueprint Medicines
had -0.004% of return per unit of risk over the last 1 month. Macroaxis philosophy towards foreseeing risk of any stock is to look at both systematic and un-systematic factors of the business, including all available market data and technical indicators
. Blueprint Medicines Corporation exposes twenty-one different technical indicators
which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm Blueprint Medicines Risk Adjusted Performance
of 0.08 and Mean Deviation of 1.88 to double-check risk estimate we provide. Macroaxis gives Blueprint Medicines performance score of 0 on a scale of 0 to 100. The firm shows Beta (market volatility) of 1.5219 which signifies that as market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, Blueprint Medicines will likely underperform.. Even though it is essential to pay attention to Blueprint Medicines historical returns, it is always good to be careful when utilizing equity current trending patterns. Macroaxis philosophy towards foreseeing future performance of any stock is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Blueprint Medicines Corporation exposes twenty-one different technical indicators which can help you to evaluate its performance. Blueprint Medicines has expected return of -0.0089%. Please be advised to confirm Blueprint Medicines Treynor Ratio as well as the relationship between Potential Upside and Expected Short fall to decide if Blueprint Medicines past performance will be repeated at some point in the near future.
|15 days auto-correlation||(0.69) |
Very good reverse predictability
Blueprint Medicines Corporation has very good reverse predictability. Overlapping area represents the amount of predictability between Blueprint Medicines time series from June 23, 2018 to July 8, 2018 and July 8, 2018 to July 23, 2018. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Blueprint Medicines price movement. The serial correlation of -0.69 indicates that around 69.0% of current Blueprint Medicines price fluctuation can be explain by its past prices. Given that Blueprint Medicines Corporation has negative autocorrelation for selected time horizon, investors may consider taking a contrarian position regarding future price movement of Blueprint Medicines for similar time interval.
|Correlation Coefficient|| -0.69|
|Spearman Rank Test|| -0.26|
|Price Variance|| 2.71|
|Lagged Price Variance|| 4.26|